Ivaltinostat

Phase 2Small molecule

MMachaon Biotherapeutics, Inc.

Ivaltinostat is one of 51 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic AdenocarcinomaActive, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

58 competitors in Pancreatic Adenocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

47 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Approved

10 3

Abraxane

Bristol-Myers Squibb

Phase 3

26 4

Taxol

Eloxatin

12 6

Mfolfirinox

Incyte

Phase 3

7 7

Opdivo

Bristol-Myers Squibb

Phase 2

7 8

Camptosar

Pfizer

Phase 2

5 9

Imfinzi

AstraZeneca

Phase 2

3 10

Yervoy

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic Adenocarcinoma1 trial

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Active, not recruiting·CCG Pharmaceuticals, Inc·Phase 1/2·NCT05249101·70 enrolled

Oral1 trial

Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule

Unknown status·MMachaon Biotherapeutics, Inc.·Phase 1·NCT05716919·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ivaltinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ivaltinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ivaltinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Machaon Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMachaon Biotherapeutics, Inc.

Ivaltinostat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic Adenocarcinoma1 trial

Oral1 trial

References

Drug Info

Quick Facts

Related News